Vindesine and mitomycin c in chemotherapy refractory advanced breast cancer

Current Status of Salvage Chemotherapy for Refractory Advanced Breast Cancer

In this era of cost containment, the benefits of all therapies are under intense scrutiny. In breast cancer management, the definitions of refractory advanced breast cancer and of its management are controversial. For the purpose of this article, refractory advanced breast cancer is partially and arbitrarily defined as primary or acquired resistance to hormonal therapies, anthracycline resistan...

First-Line Chemotherapy for Advanced Breast Cancer.

First-line chemotherapy for metastatic breast cancer has been the focus of ongoing controversy, a condition that partially reflects the imperfections of available therapy. It also partially reflects not only the imperfections in our ability to monitor response, but also the disagreements among clinicians over the goals of therapy. Each physician maintains a hierarchy of goals for the treatment ...

Neoadjuvant chemotherapy for locally advanced breast cancer.

Preoperative systemic therapy is the standard of care in locally advanced breast cancer. In this setting, the intent of preoperative systemic therapy is to expand surgical options and to improve survival. Locally advanced and inflammatory breast cancer have different biological features, but they share the use of preoperative (primary, neoadjuvant) systemic therapy as the initial treatment of c...

Advanced Gastric Carcinoma Chemotherapy with Cisplatin, Mitomycin C, BCNU, and 5-Fluorouracil in Combination

Illness perception of breast cancer in affected women undergoing chemotherapy

 Abstract Background: The aim of this study was to investigate the various aspects of illness perceptions about breast cancer in affected patients. Methods: A cross-sectional study enrolled 140 patients with breast cancer in their chemotherapy period within 14 months. The revised Illness Perception Questionnaire (revised IPQ) was used to assess the disease representations of breast cancer. The ...